Want to see KROS full AI Analyst Report?
Top Page
Keros Therapeutics
(NASDAQ:KROS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$11.00
▼(-5.74% Downside)
Action:Reiterated
Date:06/26/26
The score is held back primarily by unstable earnings and cash flow (strong 2025 followed by weak TTM results and renewed cash burn), despite a conservatively financed balance sheet. Technicals are neutral-to-soft with the stock below longer-term moving averages, and valuation is constrained by a negative P/E and no dividend yield. Corporate events are mildly positive but not enough to offset fundamental volatility.
Positive Factors
Conservative balance sheet
Very low leverage (TTM debt ~$16.3M vs equity ~$285.6M; debt-to-equity ~0.03–0.06) provides financial flexibility to fund clinical programs and absorb development setbacks. This reduces near-term refinancing risk and supports program continuity over the next several months.
Negative Factors
Earnings and revenue volatility
A sharp swing from profitable 2025 to a loss-making TTM shows results are driven by irregular events (one-time milestones or nonrecurring items). Such volatility undermines revenue predictability and complicates multi-quarter planning for R&D and capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage (TTM debt ~$16.3M vs equity ~$285.6M; debt-to-equity ~0.03–0.06) provides financial flexibility to fund clinical programs and absorb development setbacks. This reduces near-term refinancing risk and supports program continuity over the next several months.
Read all positive factors
Keros Therapeutics (KROS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$233.54M
Dividend YieldN/A
Average Volume (3M)284.67K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-84.55%
EPS Growth-1998.74%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.44
Shares Outstanding19,791,838
10 Day Avg. Volume384,198
30 Day Avg. Volume284,668
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.12
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$19.00Price Target Upside62.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-6
Revenue Forecast (FY)$4.24M
Keros Therapeutics Business Overview & Revenue Model
Company Description
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack...
How the Company Makes Money
Keros Therapeutics does not have product sales and, as a clinical-stage biotech, historically has generated limited revenue. Its revenue, when present, primarily comes from collaboration and license arrangements (e.g., upfront payments, research f...
Keros Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.18M | 244.06M | 3.55M | 151.00K | 0.00 | 20.10M |
| Gross Profit | 32.01M | 242.55M | 3.55M | 151.00K | 0.00 | 20.10M |
| EBITDA | -88.74M | 93.41M | -185.82M | -152.18M | -104.00M | -56.35M |
| Net Income | -85.14M | 87.01M | -187.35M | -152.99M | -104.68M | -58.74M |
Balance Sheet | ||||||
| Total Assets | 312.29M | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M |
| Cash, Cash Equivalents and Short-Term Investments | 281.50M | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M |
| Total Debt | 16.31M | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M |
| Total Liabilities | 26.66M | 34.89M | 44.33M | 37.81M | 29.36M | 12.08M |
| Stockholders Equity | 285.63M | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M |
Cash Flow | ||||||
| Free Cash Flow | -58.25M | 105.95M | -162.80M | -126.97M | -71.30M | -63.17M |
| Operating Cash Flow | -57.20M | 107.50M | -160.87M | -124.51M | -70.06M | -62.15M |
| Investing Cash Flow | -1.06M | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M |
| Financing Cash Flow | -380.79M | -378.47M | 391.82M | 178.96M | 120.31M | 28.55M |
Keros Therapeutics Technical Analysis
Positive
11.67
Price Trends
10.99
Positive
11.65
Positive
14.65
Negative
Market Momentum
0.25
Negative
60.93
Neutral
88.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Positive. The current price of 11.67 is above the 20-day moving average (MA) of 10.89, above the 50-day MA of 10.99, and below the 200-day MA of 14.65, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 88.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KROS.
Keros Therapeutics Risk Analysis
Keros Therapeutics disclosed 77 risk factors in its most recent earnings report. Keros Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Keros Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $726.91M | -88.02 | -6.27% | ― | 16.30% | -182.23% | |
59 Neutral | $2.08B | -34.53 | -56.87% | ― | ― | ― | |
59 Neutral | $2.39B | -6.62 | -64.21% | ― | -58.40% | -31.99% | |
56 Neutral | $1.90B | -10.33 | -35.89% | ― | ― | -63.41% | |
53 Neutral | $233.54M | -4.77 | -17.04% | ― | -84.55% | -1998.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
KROS
Keros Therapeutics
11.80
-2.77
-19.01%
GYRE
Gyre Therapeutics
6.52
-1.09
-14.32%
PVLA
Palvella Therapeutics
144.76
117.21
425.44%
NRIX
Nurix Therapeutics
23.06
10.37
81.72%
BCAX
Bicara Therapeutics Inc.
28.91
18.73
183.99%
Keros Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Keros Therapeutics Appoints Anne Prener to Board
Positive
Jun 25, 2026
On June 23, 2026, Keros Therapeutics’ board of directors appointed Anne Prener, M.D., Ph.D., as a Class III director, effective July 1, 2026, with a term running through the 2029 annual meeting. Keros announced the move publicly on June 25, ...
Executive/Board ChangesShareholder Meetings
Keros Therapeutics Stockholders Approve Directors and Governance Matters
Positive
Jun 3, 2026
On June 3, 2026, Keros Therapeutics stockholders held their 2026 Annual Meeting, where they elected Jean-Jacques Bienaimé and Charles Newton as directors to serve until the 2029 Annual Meeting, with substantial majorities of votes cast in the...
Business Operations and Strategy
Keros Therapeutics CEO to Present at Goldman Sachs Conference
Positive
Jun 1, 2026
On June 1, 2026, Keros Therapeutics, Inc. announced that its president and chief executive officer, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 4:00 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.